Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. (1st October 2020)

• Record Type: Journal Article
• Authors: Stallard, Nigel; Hampson, Lisa; Benda, Norbert; Brannath, Werner; Burnett, Thomas; Friede, Tim; Kimani, Peter K.; Koenig, Franz; Krisam, Johannes; Mozgunov, Pavel; Posch, Martin; Wason, James; Wassmer, Gernot; Whitehead, John; Williamson, S. Faye; Zohar, Sarah; Jaki, Thomas
• Is Part Of: Statistics in biopharmaceutical research. Volume 12:Number 4(2020)
• Page Start: 483
• Page End: 497
• Publication Date: 2020-10-01
• Subjects: Adaptive trial -- Group sequential design -- Multi-arm multi-stage -- Pandemic research -- Platform trial -- SARS-CoV-2; Pharmacy -- Statistical methods -- Periodicals; Pharmaceutical biotechnology -- Statistical methods -- Periodicals; Biopharmaceutics -- Periodicals; Biometry -- Periodicals; Pharmacy -- Statistical methods; Periodicals; 615.190727
• DOI: 10.1080/19466315.2020.1790415
• Languages: English
• ISSNs: 1946-6315

Abstract

ABSTRACT: The COVID-19 pandemic has led to an unprecedented response in terms of clinical research activity. An important part of this research has been focused on randomized controlled clinical trials to evaluate potential therapies for COVID-19. The results from this research need to be obtained as rapidly as possible. This presents a number of challenges associated with considerable uncertainty over the natural history of the disease and the number and characteristics of patients affected, and the emergence of new potential therapies. These challenges make adaptive designs for clinical trials a particularly attractive option. Such designs allow a trial to be modified on the basis of interim analysis data or stopped as soon as sufficiently strong evidence has been observed to answer the research question, without compromising the trial's scientific validity or integrity. In this article, we describe some of the adaptive design approaches that are available and discuss particular issues and challenges associated with their use in the pandemic setting. Our discussion is illustrated by details of four ongoing COVID-19 trials that have used adaptive designs.